1. In pregnant patients with antiphospholipid antibodies, LMWH is preferred due to its safety profile and effectiveness. Monitoring for bleeding and bone density is crucial.

2. Treatment often involves low-molecular-weight heparin, avoiding warfarin for teratogenic risks. Regular coagulation tests ensure safe maternal and fetal outcomes.

3. Safety in anticoagulant therapy during pregnancy is ensured by using LMWH over warfarin, coupled with frequent monitoring of anticoagulant levels and fetal health.